PharmaCyte Biotech, Inc. (PMCB) income statement
PMCBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 14, 2026Score 7/30
$5.37−0.05 (-0.92%)
Close on Nov 18, 2026Market cap $57.65MP/E –Yield –
PharmaCyte Biotech, Inc. income statement
Ratios
Latest available, balances at Jul 31, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2026
- -45.6%
Financial strength
- Current ratio
- 40.30
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 2307.7%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.10
- Dividend yield
- –
See a number that looks wrong?